Precipitins to an aflatoxin-producing strain of Aspergillus flavus in patients with malignancy.
Serum samples from 121 patients in whom malignant disease had been diagnosed, were assayed for precipitins to fungal isolates from leukemia-associated environments. Control sera were from age-, sex-, and race-matched patients with no history of malignant disease. Sera from 36 (30%) malignancy patients and seven (6%) controls yielded a precipitin band to an aflatoxin-producing Aspergillus flavus isolate from a leukemia-associated house (x2 = 222, p less than 0.05%). No significant numbers of precipitins were obtained to either of the other fungal isolates from that and another such house. Although A. fumigatus has frequently been incriminated as a source of infection in patients with malignancy, only 9% of malignancy patients had a precipitin response to it, as did 1.6% of controls. Also, the presence of the precipitins to A. flavus was not connected with past radiation or immunosuppressive therapy. However, among patients with precipitins to A. fumigatus there was a higher death rate in the year following the study. Precipitins to A. flavus may be related to heavy environmental exposure possibly leading to aflatoxin exposure which may contribute to development of malignancy though immunosuppressive effects.
D000293:Adolescent; D000328:Adult; D000348:Aflatoxins / Q000096:biosynthesis*; D000368:Aged; D000908:Antibodies, Fungal / Q000302:isolation & purification*; D001231:Aspergillus flavus / Q000276:immunology* / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000276:immunology*; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology*; D011234:Precipitins / Q000302:isolation & purification*
D000348:Aflatoxins; D000908:Antibodies, Fungal; D011234:Precipitins